Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice

Overview

Journal J Cell Biol

Specialty Cell Biology

Date 2001 May 31

PMID 11381087

Citations 122

Authors

R Wang

L D Ferrell

S Faouzi

J J Maher

J M Bishop

Affiliations

Soon will be listed here.

Abstract

Overexpression is the most common abnormality of receptor tyrosine kinases (RTKs) in human tumors. It is presumed that overexpression leads to constitutive activation of RTKs, but the mechanism of that activation has been uncertain. Here we show that overexpression of the Met RTK allows activation of the receptor by cell attachment and that this form of activation can be tumorigenic. Transgenic mice that overexpressed Met in hepatocytes developed hepatocellular carcinoma (HCC), one of the human tumors in which Met has been implicated previously. The tumorigenic Met was activated by cell attachment rather than by ligand. Inactivation of the transgene led to regression of even highly advanced tumors, apparently mediated by apoptosis and cessation of cellular proliferation. These results reveal a previously unappreciated mechanism by which the tumorigenic action of RTKs can be mediated, provide evidence that Met may play a role in both the genesis and maintenance of HCC, and suggest that Met may be a beneficial therapeutic target in tumors that overexpress the receptor.

Citing Articles

The MET Oncogene Network of Interacting Cell Surface Proteins.

Gallo S, Folco C, Crepaldi T Int J Mol Sci. 2025; 25(24.

PMID: 39769452 PMC: 11728269. DOI: 10.3390/ijms252413692.

New and Old Key Players in Liver Cancer.

Cuesta A, Palao N, Bragado P, Gutierrez-Uzquiza A, Herrera B, Sanchez A Int J Mol Sci. 2023; 24(24).

PMID: 38138981 PMC: 10742790. DOI: 10.3390/ijms242417152.

An Observatory for the Oncogene: A Guide for Targeted Therapies.

Altintas D, Comoglio P Cancers (Basel). 2023; 15(18).

PMID: 37760640 PMC: 10526818. DOI: 10.3390/cancers15184672.

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

Fernandes M, Hoggard B, Jamme P, Paget S, Truong M, Gregoire V Mol Oncol. 2023; 17(11):2257-2274.

PMID: 36799689 PMC: 10620121. DOI: 10.1002/1878-0261.13397.

MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.

Rivas S, Marin A, Samtani S, Gonzalez-Feliu E, Armisen R Int J Mol Sci. 2022; 23(22).

PMID: 36430388 PMC: 9697723. DOI: 10.3390/ijms232213898.

References

Bardelli A, Comoglio P . Scatter factor receptors are key players in a unique multistep program leading to invasive growth. Ciba Found Symp. 1997; 212:133-44; discussion 144-7. DOI: 10.1002/9780470515457.ch9. View

Woude G, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J . Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp. 1997; 212:119-30; discussion 130-2, 148-54. DOI: 10.1002/9780470515457.ch8. View

Jeffers M, Fiscella M, Webb C, Anver M, Koochekpour S, Woude G . The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A. 1998; 95(24):14417-22. PMC: 24388. DOI: 10.1073/pnas.95.24.14417. View

Park W, Dong S, Kim S, Na E, Shin M, Pi J . Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999; 59(2):307-10. View

Redfern C, Coward P, Degtyarev M, Lee E, Kwa A, Hennighausen L . Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat Biotechnol. 1999; 17(2):165-9. DOI: 10.1038/6165. View

Felsher D, Bishop J . Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A. 1999; 96(7):3940-4. PMC: 22399. DOI: 10.1073/pnas.96.7.3940. View

Schwartz M, Baron V . Interactions between mitogenic stimuli, or, a thousand and one connections. Curr Opin Cell Biol. 1999; 11(2):197-202. DOI: 10.1016/s0955-0674(99)80026-x. View

Olivero M, Valente G, Bardelli A, Longati P, FERRERO N, Cracco C . Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer. 1999; 82(5):640-3. DOI: 10.1002/(sici)1097-0215(19990827)82:5<640::aid-ijc4>3.0.co;2-6. View

Giancotti F, Ruoslahti E . Integrin signaling. Science. 1999; 285(5430):1028-32. DOI: 10.1126/science.285.5430.1028. View

10.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

11.

Stuart K, Riordan S, Lidder S, Crostella L, Williams R, Skouteris G . Hepatocyte growth factor/scatter factor-induced intracellular signalling. Int J Exp Pathol. 2000; 81(1):17-30. PMC: 2517792. DOI: 10.1046/j.1365-2613.2000.00138.x. View

12.

Okuda K . Hepatocellular carcinoma. J Hepatol. 2000; 32(1 Suppl):225-37. DOI: 10.1016/s0168-8278(00)80428-6. View

13.

Chin L, DePinho R . Flipping the oncogene switch: illumination of tumor maintenance and regression. Trends Genet. 2000; 16(4):147-50. DOI: 10.1016/s0168-9525(99)01968-x. View

14.

Di Renzo M, Olivero M, Martone T, Maffe A, Maggiora P, Stefani A . Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 2000; 19(12):1547-55. DOI: 10.1038/sj.onc.1203455. View

15.

Danilkovitch-Miagkova A, Angeloni D, Skeel A, Donley S, Lerman M, Leonard E . Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J Biol Chem. 2000; 275(20):14783-6. DOI: 10.1074/jbc.C000028200. View

16.

BISSELL D, Hammaker L, Meyer U . Parenchymal cells from adult rat liver in nonproliferating monolayer culture. I. Functional studies. J Cell Biol. 1973; 59(3):722-34. PMC: 2109108. DOI: 10.1083/jcb.59.3.722. View

17.

Cooper C, Park M, Blair D, Tainsky M, Huebner K, Croce C . Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984; 311(5981):29-33. DOI: 10.1038/311029a0. View

18.

Park M, Dean M, Kaul K, Braun M, Gonda M, Vande Woude G . Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A. 1987; 84(18):6379-83. PMC: 299079. DOI: 10.1073/pnas.84.18.6379. View

19.

Seth A, Park M, Copeland T, Oroszlan S, Woude G . Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A. 1988; 85(1):21-5. PMC: 279473. DOI: 10.1073/pnas.85.1.21. View

20.

Giordano S, Di Renzo M, Narsimhan R, Cooper C, Rosa C, Comoglio P . Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene. 1989; 4(11):1383-8. View